Three studies presented at the ASH Annual Meeting and Exposition highlight the emerging role CAR T-cell therapies have in treating certain types of aggressive, refractory blood cancers.

Research in Review

The addition of a novel monoclonal antibody to ibrutinib significantly improves survival outcomes for patients with previously treated high-risk chronic lymphocytic leukemia (CLL), according to the results of a phase III GENUINE trial (NCT02301156).

-----

Related Content

Read More

An intravenous consolidation regimen developed for patients with chronic lymphocytic leukemia (CLL) was found to be safe and effective, according to a report in the European Journal of Hematology (2017;98[3]:254-262).

-----

Related Content

Read More

Mutations in the BTK and PLCG2 genes have the potential to be used as a biomarker for relapse of chronic lymphocytic leukemia (CLL) after treatment with ibrutinib, according to a retrospective review published in the Journal of Clinical Oncology (published online February 13, 2017; doi:10.1200/JCO.2016.70.2282).
-----
Related Content

Read More

Genomic profiling should be applied to patients with histiocytic disorders at diagnosis in order to guide targeted therapy, according to research published in the Journal of Clinical Investigation Insight (February 2017;2[3]:e89473).

Read More

Subscribe to CAR-T Therapies